Skip navigation
Browsing by Author Yu, E. Y.
Showing results 1 to 2 of 2
| Preview | Issue Date | Title / Name | Author(s) |
| Dec-2013 | Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial | Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V. B.; Efstathiou, E.; Oudard, S.; Morris, M. J.; Goebell, P. J.; Heidenreich, A.; de Bono, J. S.; Begbie, S.; et. al; Begbie, Stephen | |
| 8-Aug-2025 | Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer | Mehra, N.; Antonarakis, E. S.; Park, S. H.; Goh, J. C.; McDermott, R.; Gonzalez, N. S.; Fong, P. C.; Griel, R.; De Santis, M.; Yanez, P. E.; Huang, Y. H.; Begbie, S. D.; Rey, F.; Kramer, G.; Suzuki, H.; Saretsky, T. L.; Ghate, S. R.; Cui, Y.; Hosius, C.; Yu, E. Y.; Begbie, Stephen | |
